These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 18342102

  • 1. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J, Mateus C, Wechsler J, Spatz A, Robert C.
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract] [Full Text] [Related]

  • 2. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.
    J Natl Cancer Inst; 2008 Feb 20; 100(4):282-4. PubMed ID: 18270341
    [No Abstract] [Full Text] [Related]

  • 3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov 20; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 4. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A, Staehler M, Eames T.
    Hautarzt; 2010 Aug 20; 61(8):662-7. PubMed ID: 20631979
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B, Kerr H.
    Dermatol Ther; 2011 Aug 20; 24(4):396-400. PubMed ID: 21910797
    [Abstract] [Full Text] [Related]

  • 6. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
    Minor DR.
    J Clin Oncol; 2010 Oct 20; 28(30):e619; author reply e620. PubMed ID: 20733133
    [No Abstract] [Full Text] [Related]

  • 7. Chemotherapeutic agents and the skin: An update.
    Heidary N, Naik H, Burgin S.
    J Am Acad Dermatol; 2008 Apr 20; 58(4):545-70. PubMed ID: 18342708
    [Abstract] [Full Text] [Related]

  • 8. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 9. [Cutaneous side effects of antiangiogenic agents].
    Robert C.
    Bull Cancer; 2007 Jul 20; 94 Spec No():S260-4. PubMed ID: 17846013
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.
    Thyroid; 2009 May 20; 19(5):539-40. PubMed ID: 19416001
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T.
    Lancet Oncol; 2005 Jul 20; 6(7):491-500. PubMed ID: 15992698
    [Abstract] [Full Text] [Related]

  • 17. Risk of bleeding not increased by sorafenib or sunitinib.
    Minor DR.
    Lancet Oncol; 2010 Feb 20; 11(2):112-3; author reply 113. PubMed ID: 20152763
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.
    Ann Oncol; 2008 Nov 20; 19(11):1975. PubMed ID: 18723549
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.